Applied Genetic Technologies Corp. (NASDAQ:AGTC)’s share price traded down 2.1% during trading on Thursday . The company traded as low as $15.08 and last traded at $15.22, with a volume of 55,265 shares traded. The stock had previously closed at $15.55.

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $32.00 price objective on shares of Applied Genetic Technologies Corp. in a report on Wednesday, June 22nd. Zacks Investment Research downgraded shares of Applied Genetic Technologies Corp. from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Applied Genetic Technologies Corp. in a report on Tuesday, May 10th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Applied Genetic Technologies Corp. in a report on Tuesday, May 10th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Applied Genetic Technologies Corp. in a report on Monday, April 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. Applied Genetic Technologies Corp. currently has a consensus rating of “Buy” and a consensus price target of $26.00.

The company’s market cap is $273.38 million. The firm’s 50-day moving average price is $15.43 and its 200 day moving average price is $15.33.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last posted its earnings results on Monday, May 9th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.06. The company earned $12 million during the quarter, compared to the consensus estimate of $12.98 million. During the same period last year, the company posted ($0.38) EPS. The firm’s revenue was up 4125.4% compared to the same quarter last year. On average, equities research analysts expect that Applied Genetic Technologies Corp. will post ($0.16) EPS for the current year.

Several hedge funds and institutional investors recently bought and sold shares of the company. Jennison Associates LLC boosted its position in Applied Genetic Technologies Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 677,610 shares of the company’s stock worth $13,823,000 after buying an additional 3,248 shares during the period. Globeflex Capital L P acquired a new position in shares of Applied Genetic Technologies Corp. during the fourth quarter worth about $1,189,000. CAM Group Holding A S acquired a new position in shares of Applied Genetic Technologies Corp. during the fourth quarter worth about $1,428,000. Finally, Russell Frank Co acquired a new position in shares of Applied Genetic Technologies Corp. during the fourth quarter worth about $1,541,000.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.